Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
N-(n-Butyl)deoxygalactonojirimycin (NB-DGJ) is an inhibitor of the glycolipid biosynthesis enzyme glucosylceramide synthase and the glycolipid catabolic enzymes glucocerebrosidase (GBA) and β-glucosidase 2 (GBA2).1,2,3,4,5 It also inhibits acid α-glucosidase, sucrase, maltase, and lactase.4 NB-DGJ (0.5-500 µM) reduces glycolipid levels in HL-60 and WEHI-3B cells.1 It decreases brain ganglioside levels in a Glb1-/- neonatal mouse model of GM1 gangliosidosis when administered intraperitoneally at doses of 600 and 1,200 mg/kg four times per day for three days.6 NB-DGJ (1-1,200 mg/kg per day for 35 days) increases testicular glucosylceramide levels in mice.2 NB-DGJ induces abnormal spermatid and acrosome formation, as well as reduces motility, in isolated mouse epididymal sperm when administered at doses of 15, 25, and 50 mg/kg per day.5 It also induces infertility, an effect that is reversed by withdrawal, in the same model.
WARNING This product is not for human or veterinary use.
1. .
2. .
3. .
4. .
5. .
6. .